Psychiatry

News

Consolidation in psychedelics as atai pairs with Beckley

Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.

News

Beckley Psytech's chief scientific and medical officer Dr Rob Conley

Beckley's psychedelic med inches forward in depression

UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.

News

Has trial result burst BMS' Cobenfy bubble?

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial.

News

Woman injecting herself while sat at a table

MIT team develops 'years-long' drug delivery tech

Researchers in the US have devised a new depot system that could provide months or even years of delivery from a single subcutaneous injection.

News

One of J&J's blockbuster depression hopes has flamed out

Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.

News

Supernus reports less than super data for depression drug

Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial.

Consolidation in psychedelics as atai pairs with Beckley

Beckley's psychedelic med inches forward in depression

Has trial result burst BMS' Cobenfy bubble?

MIT team develops 'years-long' drug delivery tech

One of J&J's blockbuster depression hopes has flamed out

Supernus reports less than super data for depression drug

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Psychiatry

Editor's Picks